Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation
jRCTs011180012Phase 2Completed
- Sponsor
- ICMR-Regional Medical Research Centre
- Start
- Jan 2016
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin in hematopoietic malignancies, sponsored by ICMR-Regional Medical Research Centre. Primary endpoint: Incidence of grade III-IV acute graft-versus-host disease. Started Jan 2016; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on jRCTs011180012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180012.